X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the development of TYRA-300 an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of achondroplasia.
Lead Product(s): TYRA-300
Therapeutic Area: Genetic Disease Product Name: TYRA-300
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 02, 2024
Details:
TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias, including achondroplasia.
Lead Product(s): TYRA-300
Therapeutic Area: Genetic Disease Product Name: TYRA-300
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
TYRA-200 is an oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations and resistance mutations, it is currently undergoing Phase 1 study for adults with advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.
Lead Product(s): TYRA-200
Therapeutic Area: Oncology Product Name: TYRA-200
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2023
Details:
TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias including achondroplasia.
Lead Product(s): TYRA-300
Therapeutic Area: Genetic Disease Product Name: TYRA-300
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
TYRA-300 is an FGFR3 selective inhibitor for the treatment of metastatic urothelial carcinoma of the bladder and urinary tract,is developing initially in intrahepatic cholangiocarcinoma.
Lead Product(s): TYRA-300
Therapeutic Area: Oncology Product Name: TYRA-300
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
TYRA-300 is an FGFR3-selective inhibitor designed to be agnostic to the gatekeeper mutation and has demonstrated less hyperphosphatemia mediated by FGFR1 inhibition than pan-FGFR inhibitors in preclinical models.
Lead Product(s): TYRA-300
Therapeutic Area: Oncology Product Name: TYRA-300
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
TYRA-300, a selective inhibitor of FGFR3, for the treatment of FGFR3-driven cancers initially for patients with bladder cancer who are resistant to FGFR therapies. TYRA-300 has demonstrated potency against both wild-type and resistant FGFR3 targets.
Lead Product(s): TYRA-300
Therapeutic Area: Oncology Product Name: TYRA-300
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Carlsbad
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 20, 2021
Details:
Financing will used to discover and develop new small molecule therapies targeting acquired resistance in oncology.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alta Partners
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
